Product Information
TRIFLUOPERAZINE 2 MG TABLET is a generic product labeled by Sandoz Inc., priced at $0.5787 per EA under NDC 00781803201. Its NADAC has been published 225 times since Mar 13, 2019.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Sandoz Inc.NDC
00781803201
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TRIFLUOPERAZINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA085786FDA Approved
Before 1982
TE Code
AB
On Market Since
11/20/1981
Pharmacological Classes
Price Statistics
The NADAC for TRIFLUOPERAZINE 2 MG TABLET has been published 225 times since Mar 13, 2019, and over the history we have for it it has declined 29.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5787 per EA |
|---|---|
| All-time high | $0.8266 (Mar 13, 2024) |
| All-time low | $0.5787 (Sep 23, 2026) |
| 52-week high | $0.6752 |
| 52-week low | $0.5787 |
| Median price | $0.7013 |
| Average price | $0.7267 |
| Largest weekly change | +18.0% (Oct 18, 2023) |
| Weeks tracked | 225 |
| Tracking since | Mar 13, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Trifluoperazine Hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sandoz Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Trifluoperazine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phenothiazine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRIFLUOPERAZINE 2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRIFLUOPERAZINE 2 MG TABLET, manufactured by Sandoz Inc., is $0.5787 per EA (NDC 00781803201), effective Sep 30, 2026.
How has the price of TRIFLUOPERAZINE 2 MG TABLET changed over time?
Over the history we have for it, the NADAC for TRIFLUOPERAZINE 2 MG TABLET has declined 29.9%. It has been tracked across 225 weekly CMS publications since Mar 13, 2019.
What are the highest and lowest recorded NADAC prices for TRIFLUOPERAZINE 2 MG TABLET?
Since Mar 13, 2019, the NADAC for TRIFLUOPERAZINE 2 MG TABLET has ranged from a low of $0.5787 (Sep 23, 2026) to a high of $0.8266 (Mar 13, 2024), with a median of $0.7013 per EA.
Are there cheaper alternatives to TRIFLUOPERAZINE 2 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of TRIFLUOPERAZINE 2 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TRIFLUOPERAZINE 2 MG TABLET?
TRIFLUOPERAZINE 2 MG TABLET (NDC 00781803201) is labeled by Sandoz Inc., and CMS classifies it as a generic product.